{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:20:50Z","timestamp":1789402850439,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12308-025-00665-3","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:33:45Z","timestamp":1762536825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Age, gender, and ethnicity are associated with higher all-cause mortality in hospitalized patients with heparin-induced thrombocytopenia: a nationwide analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Michelle","family":"Devlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Movahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrtash","family":"Hashemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoosh","family":"Hashemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"665_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1055\/s-0038-1656329","volume":"68","author":"J Amiral","year":"1992","unstructured":"Amiral J et al (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95\u201396","journal-title":"Thromb Haemost"},{"key":"665_CR2","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","volume":"83","author":"J Kelton","year":"1994","unstructured":"Kelton J (1994) Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232\u20133239","journal-title":"Blood"},{"key":"665_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1600-0609.2005.00621.x","volume":"76","author":"D Juhl","year":"2006","unstructured":"Juhl D et al (2006) Incidence and clinical significance of anti-PF4\/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76:420\u2013426","journal-title":"Eur J Haematol"},{"key":"665_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.1989.tb00258.x","volume":"73","author":"BH Chong","year":"1989","unstructured":"Chong BH, Fawaz I, Chesterman CN, Berndt MC (1989) Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 73:235\u2013240","journal-title":"Br J Haematol"},{"key":"665_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood.V96.1.188","volume":"96","author":"M Hughes","year":"2000","unstructured":"Hughes M et al (2000) Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 96:188\u2013194","journal-title":"Blood"},{"key":"665_CR6","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1182\/blood-2011-06-359430","volume":"119","author":"RS Kasthuri","year":"2012","unstructured":"Kasthuri RS (2012) PF4\/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc\u03b3RI. Blood 119:5285\u20135293","journal-title":"Blood"},{"key":"665_CR7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187008","volume":"142","author":"S Ajitha","year":"2023","unstructured":"Ajitha S et al (2023) Trends in heparin-induced thrombocytopenia in the pre-pandemic and peak-pandemic era, and impact of COVID-19 on mortality; an analysis via the national inpatient sample. Blood 142:5519\u20135519","journal-title":"Blood"},{"key":"665_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1160\/TH08-05-0312","volume":"100","author":"S Baroletti","year":"2008","unstructured":"Baroletti S (2008) Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost 100:1130\u20131135","journal-title":"Thromb Haemost"},{"key":"665_CR9","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/jth.14587","volume":"17","author":"AM Pishko","year":"2019","unstructured":"Pishko AM et al (2019) The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost 17:1956\u20131965","journal-title":"J Thromb Haemost"},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s11739-023-03379-5","volume":"18","author":"B Cosmi","year":"2023","unstructured":"Cosmi B (2023) Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital. Intern Emerg Med 18:1971\u20131980","journal-title":"Intern Emerg Med"},{"key":"665_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30046-2","volume":"5","author":"B Dhakal","year":"2018","unstructured":"Dhakal B et al (2018) Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol 5:e220\u2013e231","journal-title":"Lancet Haematol"},{"key":"665_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.athoracsur.2005.12.063","volume":"82","author":"C Wan","year":"2006","unstructured":"Wan C et al (2006) Clinical presentation, temporal relationship, and outcome in thirty-three patients with type 2 heparin-induced thrombocytopenia after cardiotomy. Ann Thorac Surg 82:21\u201326","journal-title":"Ann Thorac Surg"},{"key":"665_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","volume":"96","author":"TE Warkentin","year":"2000","unstructured":"Warkentin TE et al (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703\u20131708","journal-title":"Blood"},{"key":"665_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<90::AID-AJH4>3.0.CO;2-0","volume":"52","author":"J Amiral","year":"1996","unstructured":"Amiral J (1996) Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 52:90\u201395","journal-title":"Am J Hematol"},{"key":"665_CR15","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1182\/blood-2008-10-186064","volume":"113","author":"TE Warkentin","year":"2009","unstructured":"Warkentin TE, Sheppard J-AI, Moore JC, Cook RJ, Kelton JG (2009) Studies of the immune response in heparin-induced thrombocytopenia. Blood 113:4963\u20134969","journal-title":"Blood"},{"key":"665_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","volume":"101","author":"TE Warkentin","year":"1996","unstructured":"Warkentin TE, Kelton JG (1996) A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502\u2013507","journal-title":"Am J Med"},{"key":"665_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5","volume":"56","author":"S Nand","year":"1997","unstructured":"Nand S (1997) Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 56:12\u201316","journal-title":"Am J Hematol"},{"key":"665_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.jvca.2013.07.021","volume":"28","author":"M Seigerman","year":"2014","unstructured":"Seigerman M, Cavallaro P, Itagaki S, Chung I, Chikwe J (2014) Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: an analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 28:98\u2013102","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1160\/TH04-12-0825","volume":"94","author":"A Greinacher","year":"2005","unstructured":"Greinacher A et al (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 94:132\u2013135","journal-title":"Thromb Haemost"},{"key":"665_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","volume":"332","author":"TE Warkentin","year":"1995","unstructured":"Warkentin TE et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330\u20131336","journal-title":"N Engl J Med"},{"key":"665_CR21","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","volume":"106","author":"N Martel","year":"2005","unstructured":"Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710\u20132715","journal-title":"Blood"},{"key":"665_CR22","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","volume":"108","author":"TE Warkentin","year":"2006","unstructured":"Warkentin TE (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108:2937\u20132941","journal-title":"Blood"},{"key":"665_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/nep.14138","volume":"28","author":"C Ghimire","year":"2023","unstructured":"Ghimire C (2023) In-hospital mortality of heparin-induced thrombocytopenia in end-stage kidney disease. A retrospective national population-based cohort study. Nephrology 28:168\u2013174","journal-title":"Nephrology"},{"key":"665_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","volume":"4","author":"GK Lo","year":"2006","unstructured":"Lo GK (2006) Evaluation of pretest clinical score (4 T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759\u2013765","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00665-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00665-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:33:45Z","timestamp":1762536825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00665-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00665-3","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"value":"1868-9256","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"NIS is a public database and is IRB exempt.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"51"}}